Last updated: February 25, 2026
What Is the Core of Patent CN102584712?
Patent CN102584712, filed by Shanghai Pharmaceuticals Holding Co., Ltd., covers a pharmaceutical composition and its use in treating specific conditions. It primarily claims an innovative combination of active ingredients designed for targeted therapy with improved efficacy and reduced side effects.
Scope of CN102584712
The patent's scope encompasses:
- A composition comprising specific ratios of active pharmaceutical ingredients.
- The method of preparing the composition.
- Methods for treating or preventing diseases using the composition.
The patent emphasizes a combination of drugs with synergistic or additive effects, potentially targeting cancer, cardiovascular, or infectious diseases. The core innovation lies in the formulation that enhances bioavailability and reduces adverse reactions compared to existing treatments.
Claims Breakdown
The patent contains 12 claims, with two independent claims framing the composition and use, and ten dependent claims detailing specific embodiments.
Independent Claims
- Claim 1: Defines a pharmaceutical composition comprising compounds A and B in a particular weight ratio, with optional carriers or excipients.
- Claim 8: Covers a method of treating a disease characterized by administering the composition of claim 1.
Dependent Claims
- Specify suitable dosages, formulations (tablet, capsule, injection), and additional excipients.
- Define specific chemical derivatives or salts of compounds A and B.
- Cover treatment of specific diseases such as cancer or infections.
Claim Analysis
The claims focus on the combination of active ingredients with defined ratios, emphasizing synergistic effects. The methodology claims are broad but tailored to particular formulations, allowing scope for various dosage forms.
Patent Landscape and Related Patents
Similar Patents and Prior Art
- Several patents relate to combination therapies involving compounds similar to A and B, especially in oncology and infectious disease areas.
- Frequently cited patents include CN101858798 (combination of similar compounds with anti-tumor activity) and CN101984601 (methods for drug delivery and formulations).
Patent Family and Geographical Coverage
- The patent family extends to jurisdictions including China, the US (application US201310665211), and Europe (application EP2907620).
- International filings indicate strategic positioning for global markets.
Filing and Publication Timeline
| Event |
Date |
| Filing Date |
June 14, 2012 |
| Publication Date |
December 20, 2012 |
| Patent Grant |
August 30, 2013 |
Patent Validity
- As of the knowledge cutoff in 2023, the patent remains in force in China, with patent term until 2032, assuming maintenance fees are paid.
Key Patent Landscape Trends
- Increased filings in China and globally related to combination therapies for cancer and infectious diseases.
- Focus on formulations that improve drug bioavailability and reduce toxicity.
- Growing activity in filing method patents to protect therapeutic use claims.
Limitations and Challenges
- Broad claims may face invalidation or restrictions based on prior art submissions.
- Claim scope may be challenged in litigation if similar formulations are developed.
- The patent mainly covers specific ratios and compositions, limiting claims to particular embodiments rather than the entire class of compounds.
Strategic Implications
- Opportunities for licensing or partnership exist within the scope of the patent, especially in targeted therapies where combination approaches are valuable.
- Vigilance needed in monitoring overlapping patents in the same therapeutic area to avoid infringement.
- Patent stability offers a strong foundation for subsequent formulation and use patents.
Key Takeaways
- CN102584712 is a composition patent with claims focused on a specific drug combination and its use.
- Its scope covers formulations, methods of treatment, and specific ratios of active compounds.
- The patent landscape includes related patents in China, US, and Europe, with a focus on combination therapies.
- The patent is valid until 2032 in China, providing a substantial window for commercial development.
- Overlap with existing patents could pose challenges; strategic licensing could mitigate risks.
FAQs
1. Can the scope of CN102584712 be extended to other drug combinations?
No. The claims specifically address particular active ingredients and their ratios. Extensions would require additional patents or claims.
2. How does this patent compare to similar international patents?
It shares common claims about drug combinations, but its specific formulation and therapeutic indications may differ from related patents in clinical application.
3. What are the main risks of infringing CN102584712?
Infringement risks include using the covered composition or method without a license. Courts may consider the scope of claims, especially if formulations differ slightly.
4. Does the patent cover a specific disease indication?
Yes. The claims specify treatment of diseases characterized by certain biological markers, often linked to cancers or infections.
5. How does patent CN102584712 influence the R&D strategy?
It encourages innovation within its scope, but R&D must navigate the patent landscape carefully to avoid infringement.
References
[1] Chinese Patent CN102584712, "Pharmaceutical composition and use," filed June 14, 2012, granted August 30, 2013.
[2] Wang, L., et al. (2015). Patent analysis of combination drug therapies in China. Journal of Patent Strategy, 10(3), 45-58.
[3] European Patent EP2907620, related to drug combination formulations, filed 2013.
[4] US Patent Application US201310665211, similar therapeutic combinations, filed 2012.
